October 2, 2020

Exploring Plant-Based Bioreactors for Developing COVID-19 Therapeutics and Vaccines

Biologics company iBio, is focused on developing therapeutics and vaccines using a novel plant-based system. It recently announced a worldwide licensing agreement with Planet Biotech to develop and manufacture a novel COVID-19 therapeutic called ACE2-Fc. ...

Continue Reading

September 29, 2020

The Advantages of Implementing Plant-Based Vaccines

Accelerated development of vaccines is essential to public health and pandemic preparedness, both for the current COVID-19 pandemic and future threats. iBio is developing multiple vaccine platforms — using its, readily scalable FastPharming® plant-based ...

Continue Reading

September 16, 2020

iBio’s FastPharming® Platform Produces Decoy Therapeutic to Bind to SARS-CoV-2

iBio, Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2. Recently licensed from Planet Biotechnology, the candidate is a recombinant protein made from human angiotensin converting enzyme 2 (ACE2) fused to a human immunoglobulin G Fc ...

Continue Reading

April 24, 2020

Applying Rapid Countermeasure Preparedness to Development of a Novel COVID-19 Vaccine

The COVID-19 pandemic sweeping across the globe is pushing innovation to the cutting edge throughout the biopharma industry. More rapid development of novel diagnostics, therapeutics, and vaccines is acutely needed to mitigate further spread of the virus ...

Continue Reading

April 17, 2020

Fast-Farming Pharma: How plants could speed up vaccine manufacture to tackle the COVID-19 pandemic

At the start of April 2020, the global number of confirmed COVID-19 cases was rapidly approaching 1.5 million; the death toll: over 80,000. And these numbers will likely have changed substantially since the publication of this article. A vaccine is ...

Continue Reading
1 2 3